HLA Typing For Transplant Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global HLA Typing For Transplant Market Trends and Insights

Rising Organ Transplant Volumes

The HLA Typing for Transplant market continues to gain volume support from the steady expansion of transplant procedures across major organ categories. Global solid organ transplants reached 173,727 procedures in 2024, which marked the highest level recorded by the Global Observatory on Donation and Transplantation. Kidney transplants reached 110,467, liver transplants reached 42,497, lung transplants reached 8,236, and heart transplants reached 10,287 in 2024, and each of these procedures required compatibility testing before transplantation. Donation after circulatory determination of death also expanded by 17% in 2024, which increased the share of time-sensitive deceased-donor typing events and pushed laboratories toward faster workflows^{[1]Global Observatory on Donation and Transplantation, “Organ Donation and Transplantation Worldwide: The Global Observatory on Donation and Transplantation 2024 Report,” Transplantation, pmc.ncbi.nlm.nih.gov}. Japan’s revised 2025 heart transplantation guidelines further reinforced the clinical role of HLA matching for cardiac recipients, which added another high-value testing layer in a volume-constrained but quality-driven setting. As a result, the HLA Typing for Transplant market is seeing both higher unit demand and a stronger case for rapid, high-resolution assays.

Shift Toward Precise Donor-Recipient Matching

The HLA Typing for Transplant market is moving beyond basic compatibility and toward more precise donor-recipient evaluation. Transplant centers are using epitope-based matching and molecular mismatch scoring more often because these methods support the reduction of antibody-mediated rejection and sensitization events. Research published in 2026 showed that real-time molecular mismatch estimation using rSSO-defined HLA allele strings can be applied in deceased-donor allocation workflows without delaying organ placement. This change is pushing laboratories to supplement or replace PCR-SSP outputs with full-field NGS data, especially for retransplant candidates and sensitized patients. It is also widening the clinical scope of each pre-transplant workup because more data points are being used to judge transplant suitability. That shift is giving the HLA Typing for Transplant market a stronger pull toward premium assays and more advanced interpretation software.

Expansion of Molecular HLA Testing Adoption

The HLA Typing for Transplant market has reached a stage where routine molecular testing adoption is becoming harder to reverse. NGS is increasingly functioning as the preferred method for high-resolution typing, while Sanger sequencing is being retained more often as a backup or reference tool in resource-limited settings. A 2025 study on Chinese populations showed that optimized multiplex PCR-NGS protocols delivered phase-unambiguous genotyping across 6 HLA loci, which helped address allele ambiguity in highly polymorphic populations. The same structural shift is visible in unrelated donor registries, where high-resolution characterization across 6 or more loci keeps reference laboratories committed to scaled NGS capacity even when sample volumes vary. Research published in 2025 also showed that nanopore-based workflows could type up to 96 donor samples with 99.91% accuracy, which supported the case for larger batch operations. This is helping the HLA Typing for Transplant market move further away from residual PCR-SSO workflows in centralized laboratories.

Workflow Automation in High-Throughput Transplant Labs

The HLA Typing for Transplant market is also benefiting from workflow automation, especially in laboratories that process large sample volumes. Automation is reducing technician burden, shortening review cycles, and making high-resolution typing easier to scale across transplant networks. Faster software-assisted analysis is becoming an important part of this shift because reporting speed is increasingly tied to informatics performance and not only to wet-lab throughput. GenDx reported robust high-resolution HLA typing results across both Illumina short-read and Oxford Nanopore long-read platforms in 3 independent clinical laboratory validations, which points to a more operationally flexible workflow environment^{[2]GenDx, “Application Note, Robust HLA Typing with NGSgo-ProntoAmp,” GenDx, gendx.com}. That operating flexibility matters because laboratories can expand menu depth and throughput without rebuilding every step of the process around a single platform. The HLA Typing for Transplant market therefore gains from automation not only through volume growth, but also through more durable demand for premium reagent and software contracts.

High Cost of NGS-Based HLA Typing Workflows

The HLA Typing for Transplant market still faces a meaningful cost barrier when laboratories move from older sequence-based methods to NGS. Comparative research published in 2024 showed that the transition brings more processing steps, more manual workload, and longer turnaround risk if workflows are not fully optimized. Laboratories also need to absorb maintenance expense, bioinformatics infrastructure, validation requirements, and long-term data retention obligations. In the United States, HLA typing for solid organ transplantation is treated under organ acquisition cost bundles in the Medicare MolDX framework rather than as a separately billable laboratory service, which limits direct recovery of NGS-specific costs. The cost gap remains more visible in smaller public-sector programs and lower-volume transplant centers than in large centralized reference networks. This restraint keeps the HLA Typing for Transplant market tilted toward laboratories that can spread platform and compliance costs across broader testing volumes.

Interoperability Gaps Between LIS, HLA Software, and Hospital Systems

The HLA Typing for Transplant market is also being slowed by persistent integration problems between laboratory information systems, HLA software, and hospital records. High-resolution typing creates a larger data burden, and the clinical value of that data drops when results cannot move quickly into allocation and treatment systems. HL7 International has advanced Histocompatibility and Immunogenetics reporting profiles within its genomics implementation guide, but laboratory-specific customization remains expensive and uneven across sites. Programs with bidirectional order-and-results integration can reduce transcription risk and allocation delays, while programs without that connectivity still depend on manual reconciliation. That difference is especially relevant in Europe and Asia-Pacific, where commercial software and national allocation systems do not always operate on the same data standards. This leaves the HLA Typing for Transplant market with a technical bottleneck that affects adoption speed even when clinical demand remains strong.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Products and Services: Reagents Anchor Revenue While Software Closes the Value Gap

Reagents and Consumables accounted for 70.31% share of the HLA Typing for Transplant market size in 2025, which kept this category in the leading revenue position. That share reflected the recurring purchasing pattern attached to molecular transplant diagnostics, where every workup requires fresh assay inputs across typing, crossmatch preparation, and antibody-related testing. The HLA Typing for Transplant market therefore gives reagents a more stable demand profile than instruments, because laboratories can postpone equipment upgrades but cannot avoid daily consumable use. The move toward broader and higher-resolution NGS assays is also lifting per-event reagent value because more loci are being typed and more complex compatibility questions are being addressed in routine workflows. Long-read platform launches are reinforcing that pattern because they expand the range of kits that can command premium pricing in the HLA Typing for Transplant market^{[3]Werfen, “Werfen Introduces NanoTYPE HLA-11 Plus CE, First CE-IVD HLA Typing Kit with Full-Gene Coverage for All 11 Classical HLA Genes,” Werfen, werfen.com}.

Software and Services is projected to grow at 9.38% CAGR through 2031, which makes it the fastest-growing sub-segment in this part of the HLA Typing for Transplant industry. The traditional gap between assay value capture and informatics value capture is narrowing because NGS has made software central to the commercial proposition and not just to laboratory enablement. Analysis tools now help shape vendor choice, workflow speed, data interpretation, and platform stickiness. That shift is becoming more important as laboratories ask for integrated reporting and fewer handoffs between sequencing, allele calling, and final review. EuroBio Scientific’s April 2026 agreement to acquire CareDx’s transplant lab products division points to that broader convergence, because assay kits and related workflow assets are being consolidated under the GenDx commercial structure. The HLA Typing for Transplant market is therefore giving software and services a larger role in revenue mix as vendors compete to own more of the sample-to-report path.

By Technology: NGS Moves Ahead While Long-Read Validation Gains Pace

Molecular Assay Technologies held 80.24% revenue share in 2025, which kept this category at the center of the HLA Typing for Transplant market. That broad grouping includes PCR-based methods, NGS-based methods, and Sanger sequencing, but the internal growth balance is now shifting more clearly toward NGS. NGS-based HLA typing is projected to expand at 10.52% CAGR through 2031, which places the HLA Typing for Transplant market size for this sub-segment above the overall market growth rate. The main reason is clinical demand for high-resolution allele calls that can support better donor selection and reduce the need for retesting. PCR-based approaches still hold value in rapid or screening-oriented workflows, yet they are increasingly being used as complements to sequencing rather than as full substitutes for high-resolution analysis in the HLA Typing for Transplant market.

Long-read sequencing is also moving from research and validation settings into more visible clinical positioning. GenDx reported robust high-resolution results from blood and buccal swab samples across both Illumina and Oxford Nanopore platforms in 3 independent clinical laboratory validations, which supports a more platform-agnostic commercial environment. Werfen’s May 2026 launch of NanoTYPE HLA-11 Plus as a CE-IVD product marked an important regulatory step because it was presented as the first CE-IVD full-gene HLA typing kit across all 11 classical HLA genes. PacBio also remains relevant in this shift because its HiFi sequencing offering is being positioned around 99.9% accuracy and four-field allele resolution across classical HLA loci. Sanger-based typing and non-molecular methods still retain some presence in lower-infrastructure settings, but the HLA Typing for Transplant market is increasingly rewarding workflows that deliver full-gene resolution and stronger validation support.

By Transplant Type: Solid Organ Volume Leads While HSCT Raises Resolution Needs

Solid Organ Transplantation held 65.52% revenue share in 2025, which made it the largest transplant type in the HLA Typing for Transplant market. Kidney transplantation remains the main demand source within this category because 110,467 kidney transplants were performed worldwide in 2024, and those procedures require donor and recipient typing together with compatibility assessment. Liver and lung transplantation also added to testing demand in 2024, with 42,497 liver transplants and 8,236 lung transplants recorded globally. Donation after circulatory determination of death is adding another operational layer because a larger share of deceased-donor cases now requires rapid turnaround under tighter timing windows. This keeps solid organ transplantation as the volume anchor of the HLA Typing for Transplant market, even as technology needs become more demanding.

Hematopoietic Stem Cell Transplantation is projected to grow at 9.25% CAGR through 2031, which makes it the fastest-growing transplant type in the HLA Typing for Transplant market. This growth is linked to the higher resolution standards that HSCT workflows require, especially in unrelated donor settings. The 2024 EBMT activity report showed that allogeneic hematopoietic cell transplantation in Europe reached its highest annual level and that unrelated donor procedures represented 56% of the mix. That requirement for broader and deeper allele-level matching raises reagent value, strengthens the role of NGS, and keeps HSCT a premium segment for assay vendors. The HLA Typing for Transplant market is also seeing adjacent support from cellular therapy expansion because EBMT centers treated 6,082 first CAR-T patients in 2024. As these related therapy pathways expand, HSCT continues to raise the performance standard for the wider HLA Typing for Transplant industry.

By End User: Hospital Labs Hold Scale While Reference Networks Grow Faster

Hospitals and Transplant Centers held 42.34% revenue share in 2025, which made them the largest end-user group in the HLA Typing for Transplant market. Their lead reflected direct control over transplant decisions, patient workups, and the use of accredited histocompatibility laboratories inside major clinical centers. These accounts also carry higher value because they often buy across reagent, instrument, and software lines rather than through a single product category. The HLA Typing for Transplant market therefore favors suppliers that can support validated end-to-end workflows for transplant hospitals with complex testing requirements. Research laboratories and academic institutes remain smaller in direct revenue contribution, but they still influence technology adoption because they validate new long-read and high-resolution workflows before those tools spread more widely into routine use.

Independent Reference Laboratories are projected to grow at 8.15% CAGR through 2031, which makes them the fastest-growing end-user group in the HLA Typing for Transplant market. This rise reflects the structural decision by many mid-sized and emerging-market transplant programs to outsource high-resolution typing instead of building in-house NGS infrastructure. Public and regional centers can maintain core transplant capabilities while transferring advanced sequencing work to specialized networks. Brazil’s September 2025 transplant policy revision formalized HLA testing protocols across the national transplant system, which supports more organized demand for reference laboratory services. Similar outsourcing logic is becoming more visible in Europe and Asia-Pacific where ISO-accredited sequencing operations can be difficult to sustain at smaller sites. The HLA Typing for Transplant market is therefore pushing volume toward large certified reference providers even while hospitals remain the central requestors of testing.

Geography Analysis

North America held 45.22% share of the HLA Typing for Transplant market size in 2025, which kept it in the leading regional position. The United States remains the main contributor because its transplant ecosystem links organ procurement organizations, transplant centers, and ASHI-accredited histocompatibility laboratories in a structured way. The reimbursement framework also supports procurement continuity because HLA typing costs for solid organ transplantation are embedded within organ acquisition cost bundles under Medicare rules. That structure does not remove all pricing pressure, but it gives laboratories more visibility than in many other regions. Canada is adding to regional demand through continued investment in high-resolution typing capacity, while Mexico remains earlier in development with a smaller but growing private-sector transplant base.

Europe remained the second-largest regional block in the HLA Typing for Transplant market, with Germany, the United Kingdom, and France leading by testing sophistication and institutional depth. German university hospital laboratories such as Charité Berlin, University Medical Center Mainz, and University Hospital Leipzig operate accredited transplant immunology services that support high-resolution HLA typing in clinical practice. The regional product cycle is also becoming more active as vendors position their portfolios for the regulatory transition under IVDR, and Werfen’s CE-IVD long-read launch in May 2026 is a clear example of that push. Italy, Spain, and the wider Rest of Europe are increasingly important for outsourced high-resolution services because not every transplant center can sustain in-house NGS operations at accredited scale.

Asia-Pacific is projected to grow at 8.65% CAGR through 2031, which makes it the fastest-growing geography in the HLA Typing for Transplant market. China is a major part of that expansion because 15,387 combined kidney and liver transplants from deceased donors were recorded there in 2024. Japan also supports high per-procedure value through its transplant immunogenetics framework and its revised 2025 heart transplantation guidelines that include HLA matching considerations. India and South Korea are expanding transplant capacity quickly and are creating stronger demand for outsourced molecular typing, while South America and Middle East and Africa remain smaller regional pools with Brazil and GCC countries acting as the main points of structured investment.